European Biotech Acquisition Corp (EBAC) to Combine with Oculis SA in $218M Deal

European Biotech (NASDAQ:EBAC) has entered into a definitive agreement to combine with biopharmaceutical firm Oculis at an enterprise value of $218 million. Lausanne, Switzerland-based Oculis is developing a range of therapies for eye diseases with the most advanced having entered Phase III trials. The combined company is expected to trade on the Nasdaq once the
Read More